Back to results
US 11,896,558 B2Granted
Use of an RXR agonist and taxanes in treating Her2+ cancers
AssigneesIo Therapeutics, Inc., Board of Regents, The University of Texas System
InventorsMartin E. Sanders, Powel H. Brown, Cassandra Moyer, Abhijit Mazumdar
Life of this patent
Estimating the term…
Abstract
The present specification provides improved methods of treating Her2+ cancers in which an RXR agonist and a taxane are administered to a subject having a Her2+ cancer. Thyroid hormone and other anticancer agents may also be administered. Related compositions and combination are also disclosed.
Claims11
A method of treating a Her2+ cancer in a patient in need thereof comprising administering a taxane and a RXR agonist of Formula I,
- wherein R is H, or lower alkyl of 1 to 6 carbons, or a pharmaceutically-acceptable salt thereof, to the patient.
Dependencies are inferred from the claim text.